Columbia University Irving Medical Center, New York, New York, USA.
Transfusion. 2021 May;61(5):1350-1354. doi: 10.1111/trf.16341. Epub 2021 Mar 2.
FcRn, a non-classical Fc gamma (γ) receptor (FcγR) with near ubiquitous expression, plays key roles in disease pathogenesis and progression though immunoglobulin G (IgG) transport, IgG recycling, and IgG-immune complex clearance. FcRn function can be inhibited using IgG-based and non-IgG-based antagonists, by exploiting the pH-dependent binding affinity of FcRn for the IgG Fc region. FcRn therapeutics have shown promise in murine models and human clinical trials for autoimmune diseases and maternal-fetal immune cytopenias; they appear safe, well-tolerated, and reduce circulating IgG levels. Compared to traditional therapeutics, inhibiting FcRn has fewer adverse side effects and represents a new approach that is less invasive, time-consuming, and costly.
FcRn，一种具有广泛表达的非经典 Fc γ（γ）受体（FcγR），通过 IgG 转运、IgG 再循环和 IgG-免疫复合物清除，在疾病发病机制和进展中发挥关键作用。可以使用 IgG 基和非 IgG 基拮抗剂来抑制 FcRn 的功能，利用 FcRn 对 IgG Fc 区域的 pH 依赖性结合亲和力。FcRn 疗法在自身免疫性疾病和母婴免疫性细胞减少症的小鼠模型和人体临床试验中显示出前景；它们似乎安全、耐受良好，并降低循环 IgG 水平。与传统疗法相比，抑制 FcRn 的副作用更少，代表了一种新的方法，侵入性更小、耗时更少且成本更低。
